{
    "nctId": "NCT04497285",
    "briefTitle": "Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer",
    "officialTitle": "HOPE: Real World Clinical Practice Study to Assess the Impact of Using Comprehensive Genomic Data on the Next Treatment Decision Making Choice in Patients With Locally Advanced or Metastatic Breast Cancer in Spain",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Metastatic breast cancer management based on tumor molecular profile",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female or Male patients.\n2. Age \u226518 years.\n3. Signed informed consent prior to any screening procedure.\n4. Locally advanced or metastatic breast cancer of any subtype confirmed both pathologically and radiologically (stage IIIb- IV disease).\n5. The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the healthcare setting.\n6. Availability of one metastatic (preferably), primary tumor sample or blood sample.\n7. Measurable or non-measurable disease.\n8. Quality of life score according to ECOG scale \u2264 3.\n9. Minimal life expectancy of 6 months.\n\nExclusion Criteria:\n\n1. Inability to consent or conform to the processes involved in a clinical study.\n2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}